Nathalie Baumlin
Papers
2
Total Citations
381
H-Index
2
About
Nathalie Baumlin is a leading researcher in pulmonary toxicology and respiratory epithelial biology, with a focus on the mechanisms underlying chronic lung diseases. Her work has been instrumental in understanding how environmental exposures—particularly tobacco smoke and electronic cigarette vapor—disrupt airway function. In a landmark 2016 study with 343 citations, she demonstrated that chronic e-cigarette exposure in mice induces features of chronic obstructive pulmonary disease (COPD) in a nicotine-dependent manner, providing critical evidence that vaping is not harmless and can trigger pathological changes similar to smoking. This research has shaped public health discussions and regulatory considerations around e-cigarette safety. Baumlin also investigates mucociliary dysfunction, a hallmark of COPD and cystic fibrosis. Her 2015 study showed that the PDE4 inhibitor roflumilast partially reverses smoke-induced mucociliary impairment by restoring CFTR function, offering mechanistic insight into a therapeutic strategy for airway disease. Her contributions bridge basic epithelial cell biology with translational toxicology, and her work is widely cited for its relevance to both clinical and policy audiences.
Research Focus
Key Achievements
Top Papers
- 1
- 2Roflumilast partially reverses smoke-induced mucociliary dysfunction38 citations · 2015